mTOR, a serine–threonine kinase, forms two complexes, mTORC1 and mTORC2, and is mutated in 1.8% of the primary breast cancer cases in The Cancer Genome Atlas, with a small minority of these mutations recognized as putative drivers [20,21]. This evidence concerns the gene MTOR and cancer.